Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease

How Zn can impede Cu detoxification by chelating agents in Alzheimer's disease: a proof-of-concept study

“…1,3,4 Indeed, while amyloid plaques are observed post-mortem in AD patients’ brains, the monomeric soluble Aβ peptide is present in healthy patients. Metal ions, mainly Cu( i / ii ) and Zn( ii ), have been related to alteration of the Aβ aggregation process 5,6 and both metal ions are bound to the Aβ peptide within the amyloid plaques.…”

Synthesis and evaluation of frentizole-based indolyl thiourea analogues as MAO/ABAD inhibitors for Alzheimer’s disease treatment

“…alteration in neurotransmitter systems, deposition of amyloid beta peptide (Aβ), tauprotein hyperphoshorylation with tangle formation, oxidative stress and mitochondrial dysfunction. 3,4 Most of the currently marketed drugs (namely donepezil, rivastigmine, galanthamine) prevent the degradation of acetylcholine via the inhibition of acetylcholinesterase to sustain sufficient levels in the face of the decreased numbers of cholinergic neurons in AD. 5 This approach is only effective for symptomatic treatment of mild and moderate cognitive decline and does not provide prevention of disease progression.…”

Aromatherapy and Aromatic Plants for the Treatment of Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer’s Disease: Clinical Evidence and Possible Mechanisms

“…Other forms of dementia are Lewy body dementia, frontotemporal dementia, and vascular dementia. AD is a progressive neurodegenerative disease characterized by cognitive and noncognitive dysfunctions [3]. In particular, the WHO describes dementia as a clinical syndrome due to disease of the brain, usually of a progressive nature, which leads to disturbances of multiple higher cortical functions, including memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgment.…”